Drug Target Review

JULY 23, 2024

Focusing on my time as Head of Research at Kymera, I’ve been fortunate to break new ground in drug discovery and development by advancing the science of targeted protein degradation (TPD) and progressing an industry leading pipeline to solve critical health problems that traditional medicines cannot address.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. ” About Sosei Heptares.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn., Goldman Sachs & Co.

Targeted Protein Degradation 40

Targeted Protein Degradation Engineering Clinical Trials Disease 40

Drug Hunter

AUGUST 21, 2023

Recent promising results from a Phase 2/3 trial support the use of a single oral dose of brain-penetrant acoziborole (SCYX-7158) for HAT treatment. The need to achieve CNS target coverage with a single dose makes the HAT field an excellent source of case studies for improving brain penetration, with three examples noted below.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206